Ji Hyeon Park

Ji Hyeon Park

Auto-generated profile, based on publicly available information

Ji Hyeon Park

Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital , Seoul 03080

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
JPJi Hyeon Park
Ji Hyeon Park
SPSamina Park
Samina Park
CKChang Hyun Kang
Chang Hyun Kang
BNBubse Na
Bubse Na
SBSo Young Bae
So Young Bae
PHPh.D.
Ph.D.
Ji Hyeon Park, M.D., Samina Park, M.D., Chang Hyun Kang, M.D., Ph.D., Bub Se Na, M.D., So Young Bae, M.D., Kwon Joong Na, M.D., Hyun Joo Lee, M.D., In Kyu Park, M.D., Ph.D., Young Tae Kim, M.D., Ph.D.. J Chest Surg 2022;55:49-54. https://doi.org/10.5090/jcs.21.128

23 April 2024 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
SBSeon Yong Bae
Seon Yong Bae
TYTaeyoung Yun
Taeyoung Yun
JPJi Hyeon Park
Ji Hyeon Park
BNBubse Na
Bubse Na
KNKwon Joong Na
Kwon Joong Na
YKYoung Tae Kim
Young Tae Kim
Seon Yong Bae, M.D., Taeyoung Yun, M.D., Ji Hyeon Park, M.D., Bubse Na, M.D., Kwon Joong Na, M.D., Samina Park, M.D., Hyun Joo Lee, M.D., Ph.D., In Kyu Park, M.D., Ph.D., Chang Hyun Kang, M.D., Ph.D., Young Tae Kim, M.D., Ph.D.. J Chest Surg 2024;57:450-7. https://doi.org/10.5090/jcs.24.008

5 June 2020 in The Korean Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
JPJi Hyeon Park
Ji Hyeon Park
SSSuk Ho Sohn
Suk Ho Sohn
JCJae Woong Choi
Jae Woong Choi
EPEun-Ah Park
Eun-Ah Park
HHHo Young Hwang
Ho Young Hwang
Ji Hyeon Park, M.D., Suk Ho Sohn, M.D., Jae Woong Choi, M.D., Eun Ah Park, M.D., Ph.D., Ho Young Hwang, M.D., Ph.D.. Korean J Thorac Cardiovasc Surg 2020;53:127-31. https://doi.org/10.5090/kjtcs.2020.53.3.127

1 December 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
TYTaeyoung Yun
Taeyoung Yun
BKByeong Ju Koo
Byeong Ju Koo
KNKwon Joong Na
Kwon Joong Na
SLSangjun Lee
Sangjun Lee
JPJi Hyeon Park
Ji Hyeon Park
YKYoung Tae Kim
Young Tae Kim
Objectives: To compare postoperative lung function and volume compensation in lung cancer patients after lobectomy or segmentectomy. Methods: We retrospectively reviewed patients who underwent initial lung cancer surgery between 2019 and 2021. Of 1076 patients, 870 underwent lobectomy and 206 segmentectomy. Propensity score matching (PSM) of 1:2 was performed using age, sex, smoking status, and preoperative pulmonary function tests (PFTs). Total lung volume (TLV) was calculated using deep learning-assisted 3D lung segmentation on thin-section computed tomography images. Postoperative lung volumes were compared with predicted postoperative (PPO) volumes and correlated with PFT results. Results: After matching, 378 lobectomy and 189 segmentectomy patients were included. TLV reduction was similar between groups, but contralateral lung volume (CLV) increased more after lobectomy (P = .010). Diffusing capacity of the lung for carbon monoxide was better preserved after segmentectomy (P = .029), whereas force vital capacity and forced expiratory volume in 1 second (FEV1) were similar. Actual postoperative PFT values exceeded predicted values in both groups, but the discrepancy was larger after lobectomy (P < .001). In segmentectomy, single-segment resection showed no compensation, while multiple-segment resections had variable compensation patterns. Ipsilateral lung volume changes contributed more than CLV changes, and compensation patterns varied by lobe. The TLV change correlated with forced vital capacity and FEV1 but not diffusing capacity of the lung for carbon monoxide. Conclusions: Lobectomy induced greater CLV compensation than segmentectomy. Although overall lung function preservation was similar, lobectomy resulted in a greater difference between actual and PPO pulmonary function.

1 October 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
TYTaeyoung Yun
Taeyoung Yun
SLSangjun Lee
Sangjun Lee
JPJi Hyeon Park
Ji Hyeon Park
BNBubse Na
Bubse Na
KNKwon Joong Na
Kwon Joong Na
SPSamina Park
Samina Park
Background: The potential association between preoperative percutaneous transthoracic needle biopsy (PTNB) and pleural recurrence in lung cancer remains controversial. This study aimed to determine whether PTNB increases the risk of pleural recurrence in patients with clinically diagnosed stage I non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 1,733 patients with clinical stage I NSCLC who underwent surgical resection between January 2018 and December 2020. Patients were divided into the PTNB group (n=699) and the non-PTNB group (n=1,034). After 1:1 propensity score matching (PSM), risk factors for pleural recurrence were assessed using Fine-Gray subdistribution hazard models. Cumulative incidence rate and overall survival (OS) were also analyzed. Results: After matching, 530 patients were included in each group. Multivariate Fine-Gray analysis revealed that PTNB [subdistribution hazard ratio (sHR) =3.74; 95% confidence interval (CI): 1.06–13.20; P=0.040] and visceral pleural invasion (VPI) (sHR =3.12; 95% CI: 1.10–8.90; P=0.03) were independent risk factors for isolated pleural recurrence, whereas lymphatic invasion was not (sHR =2.32; 95% CI: 0.82–6.56; P=0.11). For all types of recurrence, PTNB, VPI, and lymphatic invasion were significant predictors (all P<0.05). A subgroup analysis was conducted in patients without VPI or lymphatic invasion (n=1,142; PTNB group =332, non-PTNB group =810), representing a low-risk cohort for pleural recurrence. After PSM, 320 patients were included in each group with well-balanced baseline characteristics. In this subgroup, PTNB remained a significant risk factor for isolated pleural recurrence in the univariate Fine-Gray analysis (sHR =2.29; 95% CI: 1.19–4.38; P=0.01) and for all recurrence types (sHR =2.13; 95% CI: 1.13–4.01; P=0.01). Pathologic tumor size was also consistently associated with increased recurrence risk. In multivariate models PTNB, non-adenocarcinoma histology, and larger pathological tumor size were associated with both isolated pleural and overall recurrence (all P<0.001). Conclusions: Preoperative PTNB was statistically correlated with an increased pleural recurrence in clinical stage I NSCLC, even among patients without conventional high-risk pathological features. Careful consideration is warranted when deciding on PTNB for early-stage disease.

13 March 2024 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
HHHee Ju Hong
Hee Ju Hong
JPJi Hyeon Park
Ji Hyeon Park
SPSamina Park
Samina Park
IPIn Kyu Park
In Kyu Park
CKChang Hyun Kang
Chang Hyun Kang
YKYoung Tae Kim
Young Tae Kim
Hee Ju Hong, M.D., Ji Hyeon Park, M.D., Samina Park, M.D., In Kyu Park, M.D., Ph.D., Chang Hyun Kang, M.D., Ph.D., Young Tae Kim, M.D., Ph.D.. J Chest Surg 2024;57:342-50. https://doi.org/10.5090/jcs.23.155